Article

Conventional LASIK affects night-driving performance

Washington, DC &#8212 Conventional LASIK for moderate myopia generally reduces night-driving performance, but the frequency of that effect differs between laser platforms, said Steve C. Schallhorn, MD.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
Related Content
Phase 2 data on IBI302 announced by Innovent Biologics
May 7th 2025

Phase 2 data on IBI302 announced by Innovent Biologics

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Phase 2 BETTER trial results shared at ARVO 2025
May 7th 2025

Phase 2 BETTER trial results shared at ARVO 2025

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap
May 7th 2025

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap

RetinalGenix signs new laboratory lease with MBC BioLabs
May 7th 2025

RetinalGenix signs new laboratory lease with MBC BioLabs

© 2025 MJH Life Sciences

All rights reserved.